MEA Non-Insulin Diabetes Therapies Market

The size of the Middle East and Africa Non-Insulin Diabetes Therapies market has been estimated at USD 1.78 million in 2022 and is expected to grow at a CAGR of 4.12% to reach USD 2.18 million by 2027.

One of the key factors moving the market ahead is the increase in the number of people affected by Diabetes Type 2. By 2040, diabetes is expected to affect 642 million people. Because companies attempted to find drugs with fewer side effects, the Middle East and Africa market has increased dramatically. Non-insulin drugs help the liver produce Insulin when injected into the body. The Insulin market previously dominated; however, non-Insulin treatments will eventually overtake Insulin Type products in popularity. Diabetes is caused by a change in lifestyle and eating habits, estimated to drive market expansion in this region.

The COVID-19 pandemic is currently a severe situation, and the growing number of new positive cases is causing worldwide alarm. Scientists and pharmaceutical businesses worldwide are researching the coronavirus and its effects on the human body. The coronavirus has been discovered to impact patients who have cardiac disease or diabetes negatively. As a result, the non-insulin medicine market in the Middle East and Africa is predicted to rise during the pandemic. People will need to treat their diabetes for the coronavirus not to become a lethal catalyst that badly affects the body.

The industry's primary goal is to produce medicines with fewer side effects and greater efficacy than currently available pharmaceuticals. Many people are still unaware of the drugs' benefits, challenging public awareness. Because diabetes is such a common ailment, making these treatments accessible to people from all socioeconomic backgrounds is critical. Many people are uninformed of how medications operate and used; improving public awareness is another challenge for the pharmaceutical industry. The drugs market penetration is limited since the market leaders in this class are concentrated in a few geographic areas, resulting in low sales and awareness. The government's efforts to increase public awareness are few and far between, limiting the market's expansion.

This research report on the MEA Non-insulin diabetes therapies market has been segmented and sub-segmented into the following categories:

By Drug Type:

• Sulphonylureas     
• Amylin Agonists    
• GLP-1 Agonists & Analogs
• Biguanides             
• Glinides & Meglinitides      
• Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors       
• Thiazolidinediones (or Glitazones or TZDs )
• Alpha-Glucosidase Inhibitors         
• Dipeptidyl Peptidase-4 (DPP4) Inhibitors

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Over the forecast period, the Middle East and Africa are expected to account for a considerable global market share. Due to unhealthy lifestyles and urbanization being major causes, this region sees an increase in diabetic cases. Because of their rapid economic and industrial development, several Middle Eastern and African countries have seen a shift in their social behavior.

One factor for the upward tendency is the incidence of diabetes. In addition, several ongoing scientific investigations and improvements in alternative treatment choices and healthcare infrastructure have influenced the company's growth. Finally, to grow the company's market, foreign investors are required. These factors are predicted to be driving the Non-Insulin Diabetes Therapies market in the Middle East and Africa forward.

Oman is expected to dominate the MEA Non-Insulin Diabetes Therapies market during the forecast period. Sedentary lifestyles and unlimited fast-food options have supplanted traditional means of work, travel, and cuisine for most of the population, increasing the risk of diseases like type-2 diabetes.

South Africa is predicted to hold the most outstanding share of the MEA Non-Insulin Diabetes Therapies market, following Oman. Increased healthcare expenditures might be driven by increased population and per capita income, driving the market studied during the projection period.

KEY MARKET PLAYERS:

Tobira (New Jersey), Eli Lilly and Sumitomo Dainippon Pharma (Japan), Novo Nordisk (Denmark), Takeda (Japan), Sanofi (China), Mannkind (California), Bristol-Myers Squibb (New York), AstraZeneca (U.K), Boehringer Ingelheim (Germany), Bayer (Germany) are a few of the companies playing a leading role in the MEA non-insulin diabetes therapies market.